Investors
Invest in physiological intelligence
UbitelCare It is a company of digital healthWith its own technology, a diversified ecosystem of clinical and wellness solutions, and validation with real patients in a hospital setting. Develops platforms that transform physiological data into useful knowledge, a structurally growing market driven by the aging population and the pressure on healthcare systems.

An opportunity built on proprietary technology
UbitelCare transforms complex physiological data into useful knowledge for individuals, organizations, and healthcare systems. Its differentiating factor is not data capture —the market is full of platforms that measure— but the ability to interpret it: analyze the physiological behavior of each user Over time, identify what deviates from your usual pattern and communicate it in a structured and understandable way.
The company combines its own technological asset —software with protected intellectual property, registered as a scientific work and as a computer program, capable of processing clinical series in real time— with an ecosystem of solutions that shares the same technological base and scales by modules: cardiology, nephrology, respiratory rehabilitation and wellness. Each new solution is a module that reuses the platform without rebuilding it.
Key aspects of the business model:
- B2B last mile distribution
- Lower customer acquisition cost
- Accelerated market penetration
- High-value, long-term contracts
Four reasons to invest in Ubitelcare
Proprietary and protected technology
The core of the system are the physiological analysis algorithms, Developed by the UbitelCare team, registered and owned by the company. The strategy is Do not patent in order to avoid publishing the algorithm.The differential knowledge is protected and cannot be replicated without access to the equipment.
Diversified ecosystem
Unlike most HealthTech startups, which focus on a single pathology, UbitelCare has built an ecosystem on a single platform: cardiology, nephrology, respiratory rehabilitation and wellness. Each module adds a market without rebuilding the base technology, expands potential revenue, and reduces dependence on a single customer or sector.
Clinical validation in hospital settings
Ubicardio has been validated with real patients in the Heart Failure Unit of the Virgen Macarena University Hospital in Seville, with Clinical leadership of Dr. Alejandro Recio Mayoral. The first commercial version arrived in July 2024 and the San Juan de Dios Hospital of Aljarafe has issued a letter of institutional support.
Competitive cost and scalable model
He Standard commercial hardware with medical CE marking —without proprietary devices— and its own software in the cloud allow a competitive cost per patient compared to enterprise platforms in the sector, with recurring subscription revenues that scale with users without growing the structure in the same proportion.
Explore the investment opportunity

Current round
Do you want to delve deeper?
Request access to the complete investment dossier. It includes financial details, the business plan, projections, and confidential documentation. It is shared under a confidentiality agreement.


